The Journal of Bone and Joint Surgery, Vol 76, Issue 8 1174-1185, Copyright © 1994 by Journal of Bone and Joint Surgery, Inc

JOURNAL CONTENTS

RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group

The efficacy and safety of RD heparin, a low-molecular-weight heparin, for the prevention of venous thromboembolic disease among patients managed with an elective total hip or total knee arthroplasty were compared with the efficacy and safety of warfarin in an open-label prospective, multicenter trial. Patients were randomized to receive either a fixed dose of fifty anti-factor-Xa units of RD heparin per kilogram of body weight, administered subcutaneously twice daily, beginning postoperatively; a fixed dose of ninety anti-factor-Xa units of RD heparin per kilogram of body weight, administered subcutaneously once daily, beginning postoperatively; or five milligrams of warfarin, administered orally preoperatively, followed by a daily adjusted dose of warfarin to prolong the prothrombin time ratio to 1.2 to 1.5. The primary measure of efficacy was contrast venography of the treated limb, performed by local radiologists blinded to the type of treatment that had been assigned. Nine hundred and sixty-nine patients had a complete assessment for the presence of deep-vein thrombosis. The over-all rates of venous thromboembolic disease were 16 percent (95 pecent confidence interval, 13 to 21 percent) (fifty-three) for the 328 patients who received RD heparin twice daily, 21 percent (95 percent confidence interval, 17 to 26 percent) (sixty-eight) for the 320 patients who received RD heparin once daily, and 27 percent (95 percent confidence interval, 22 to 32 percent) (eighty-seven) for the 321 patients who received warfarin (p < 0.001 for RD heparin administered twice daily compared with warfarin; p = 0.13 for RD heparin administered once daily compared with warfarin). Compared with warfarin, RD heparin administered twice daily and RD heparin administered once daily reduced the risk of venous thromboembolic disease by 41 percent (95 percent confidence interval, 20 to 56 percent) and 18 percent (95 percent confidence interval, -6 to 37 percent), respectively. The rates of venous thromboembolic disease after 523 total hip arthroplasties were 8, 14, and 14 percent for the patients who received RD heparin twice daily, those who received it once daily, and those who received warfarin (p = 0.07 for RD heparin administered twice daily compared with warfarin; p = 0.82 for RD heparin administered once daily compared with warfarin).(ABSTRACT TRUNCATED AT 400 WORDS)
CiteULike    Connotea    Del.icio.us    Technorati    What's this?

This article has been cited by other articles:

				W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 381S - 453S. [Abstract] [Full Text] [PDF]

				C. W. Colwell Jr., S. D. Berkowitz, J. R. Lieberman, P. C. Comp, J. S. Ginsberg, G. Paiement, J. McElhattan, A. W. Roth, C. W. Francis, and The EXULT B Study Group Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty J. Bone Joint Surg. Am., October 1, 2005; 87(10): 2169 - 2177. [Abstract] [Full Text] [PDF]

				J. R. Lieberman and W. K. Hsu Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2097 - 2112. [Abstract] [Full Text] [PDF]

				G. Agnelli Prevention of Venous Thromboembolism in Surgical Patients Circulation, December 14, 2004; 110(24_suppl_1): IV-4 - IV-12. [Abstract] [Full Text] [PDF]

				M. McGuire and P. P. Dobesh Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 289 - 307. [Abstract] [PDF]

				W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 338S - 400S. [Abstract] [Full Text] [PDF]

				B. L. Davidson, S. D. Sullivan, S. R. Kahn, L. Borris, P. Bossuyt, and G. Raskob The Economics of Venous Thromboembolism Prophylaxis: A Primer for Clinicians Chest, December 1, 2003; 124(6_suppl): 393S - 396S. [Abstract] [Full Text] [PDF]

				C. W. Francis, S. D. Berkowitz, P. C. Comp, J. R. Lieberman, J. S. Ginsberg, G. Paiement, G. R. Peters, A. W. Roth, J. McElhattan, C. W. Colwell Jr., et al. Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement N. Engl. J. Med., October 30, 2003; 349(18): 1703 - 1712. [Abstract] [Full Text] [PDF]

				C. W. Francis, B. L. Davidson, S. D. Berkowitz, P. A. Lotke, J. S. Ginsberg, J. R. Lieberman, A. K. Webster, J. P. Whipple, G. R. Peters, and C. W. Colwell Jr. Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty: A Randomized, Double-Blind Trial Ann Intern Med, October 15, 2002; 137(8): 648 - 655. [Abstract] [Full Text] [PDF]

				P. Prandoni, O. Bruchi, P. Sabbion, C. Tanduo, A. Scudeller, C. Sardella, G. Errigo, F. Pietrobelli, G. Maso, and A. Girolami Prolonged Thromboprophylaxis With Oral Anticoagulants After Total Hip Arthroplasty: A Prospective Controlled Randomized Study Arch Intern Med, September 23, 2002; 162(17): 1966 - 1971. [Abstract] [Full Text] [PDF]

				T. P. Sculco, C. W. Colwell Jr., V. D. Pellegrini Jr., G. H. Westrich, and F. Bottner Prophylaxis Against Venous Thromboembolic Disease in Patients Having a Total Hip or Knee Arthroplasty J. Bone Joint Surg. Am., March 1, 2002; 84(3): 466 - 477. [Full Text]

				J. A. Heit, C. W. Colwell, C. W. Francis, J. S. Ginsberg, S. D. Berkowitz, J. Whipple, G. Peters, and for the AstraZeneca Arthroplasty Study Group Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Phase 2 Dose-Finding Study Arch Intern Med, October 8, 2001; 161(18): 2215 - 2221. [Abstract] [Full Text] [PDF]

				R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, W. A. Ghali, M. S. Butcher, R. F. Brant, D. Bergqvist, et al. Timing of Initial Administration of Low-Molecular-Weight Heparin Prophylaxis Against Deep Vein Thrombosis in Patients Following Elective Hip Arthroplasty: A Systematic Review Arch Intern Med, September 10, 2001; 161(16): 1952 - 1960. [Abstract] [Full Text] [PDF]

				R. H. Fitzgerald, T. E. Spiro, A. A. Trowbridge, G. A. Gardiner Jr., T. L. Whitsett, M. B. O'Connell, J. A. Ohar, and T. R. Young Prevention of Venous Thromboembolic Disease Following Primary Total Knee Arthroplasty : A Randomized, Multicenter, Open-Label, Parallel-Group Comparison of Enoxaparin and Warfarin J. Bone Joint Surg. Am., June 1, 2001; 83(6): 900 - 906. [Abstract] [Full Text]

				A. E. Bajjoka, R. Hull, G. Pineo, C. Francis, D. Bergqvist, C. Fellenius, A. Mah, and R. Brant Dalteparin vs Warfarin in Hip Arthroplasty Patients Arch Intern Med, March 12, 2001; 161(5): 776 - 777. [Full Text] [PDF]

				P. C. Comp, T. E. Spiro, R. J. Friedman, T. L. Whitsett, G. J. Johnson, G. A. Gardiner, G. C. Landon, and M. Jové Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement J. Bone Joint Surg. Am., March 1, 2001; 83(3): 336 - 336. [Abstract] [Full Text]

				G. K Bell and S. Z Goldhaber Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement Vascular Medicine, February 1, 2001; 6(1): 23 - 29. [Abstract] [PDF]

				J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]

				W. H. Geerts, J. A. Heit, G. P. Clagett, G. F. Pineo, C. W. Colwell, F. A. Anderson Jr., and H. B. Wheeler Prevention of Venous Thromboembolism Chest, January 1, 2001; 119(1_suppl): 132S - 175S. [Full Text] [PDF]

				K. B. Freedman, K. R. Brookenthal, R. H. Fitzgerald, S. Williams, and J. H. Lonner A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty J. Bone Joint Surg. Am., July 1, 2000; 82(7): 929 - 929. [Abstract] [Full Text]

				J. A. Heit, C. G. Elliott, A. A. Trowbridge, B. F. Morrey, M. Gent, J. Hirsh, and for the Ardeparin Arthroplasty Study Group* Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, June 6, 2000; 132(11): 853 - 861. [Abstract] [Full Text] [PDF]

				B. L. Davidson and A. W.A. Lensing Prolonged Prophylaxis after Joint Replacement: Another Step Sideways? Ann Intern Med, June 6, 2000; 132(11): 914 - 915. [Full Text] [PDF]

				S. Z. Goldhaber, R. B. Morrison, L. L. Diran, M. A. Creager, and T. H. Lee Jr Abbreviated Hospitalization for Deep Venous Thrombosis With the Use of Ardeparin Arch Intern Med, November 23, 1998; 158(21): 2325 - 2328. [Abstract] [Full Text] [PDF]

				D. WARWICK, J. HARRISON, D. GLEW, A. MITCHELMORE, T. J. PETERS, and J. DONOVAN Comparison of the Use of a Foot Pump with the Use of Low-Molecular-Weight Heparin for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement. A Prospective, Randomized Trial J. Bone Joint Surg. Am., August 1, 1998; 80(8): 1158 - 66. [Abstract] [Full Text]

				J. R. Leclerc, M. Gent, J. Hirsh, W. H. Geerts, J. S. Ginsberg, and for the Canadian Collaborative Group The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin: A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty Arch Intern Med, April 27, 1998; 158(8): 873 - 878. [Abstract] [Full Text] [PDF]

				J. I. Weitz Low-Molecular-Weight Heparins N. Engl. J. Med., September 4, 1997; 337(10): 688 - 699. [Full Text] [PDF]

				C. W. FRANCIS, V. D. PELLEGRINI JR., S. TOTTERMAN, A. D. BOYD JR., V. J. MARDER, K. M. LIEBERT, B. N. STULBERG, D. C. AYERS, A. ROSENBERG, C. KESSLER, et al. Prevention of Deep-Vein Thrombosis after Total Hip Arthroplasty. Comparison of Warfarin and Dalteparin J. Bone Joint Surg. Am., September 1, 1997; 79(9): 1365 - 72. [Abstract] [Full Text]

				J.R. Leclerc State-of-the-Art Review: Low-Molecular Weight Heparin Prophylaxis in Surgical Patients Clinical and Applied Thrombosis/Hemostasis, July 1, 1997; 3(3): 153 - 156. [PDF]

				J. R. LIEBERMAN, J. WOLLAEGER, F. DOREY, B. J. THOMAS, D. J. KILGUS, M. J. GRECULA, G. A. FINERMAN, and H. C. AMSTUTZ The Efficacy of Prophylaxis with Low-Dose Warfarin for Prevention of Pulmonary Embolism following Total Hip Arthroplasty J. Bone Joint Surg. Am., March 1, 1997; 79(3): 319 - 25. [Abstract] [Full Text]

				D. C. AYERS, D. A. DENNIS, N. A. JOHANSON, and V. D. PELLEGRINI JR. Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Common Complications of Total Knee Arthroplasty*{{dagger}} J. Bone Joint Surg. Am., February 1, 1997; 79(2): 278 - 311. [Full Text]

				S. T. WOOLSON Intermittent Pneumatic Compression Prophylaxis for Proximal Deep Venous Thrombosis after Total Hip Replacement J. Bone Joint Surg. Am., November 1, 1996; 78(11): 1735 - 40. [Abstract] [Full Text]

				P. Prandoni, S. Z. Goldhaber, A. Piccioli, and A. Girolami State-of-the-Art Review : Prevention of Venous Thromboembolism in Major Orthopedic Surgery Clinical and Applied Thrombosis/Hemostasis, July 1, 1996; 2(3): 153 - 157. [Abstract] [PDF]